|
Marinomed - Austrian Visual Worldwide Roadshow 2021
„ Marinomed - Solving the unsolvable with radical innovation “
„ Marinomed - Disclaimer “
„ Marinomed - Highlights “
„ Marinomed - Q1 Highlights “
„ Marinomed - Market “
„ Marinomed - Snapshot on business drivers “
„ Marinomed - R&D progress/pipeline “
„ Marinomed - Marinomed pipeline “
„ Marinomed - Carragelose neutralizes SARS-CoV-2 in vitro “
„ Marinomed - SARS-CoV-2 prophylaxis trial in health care professionals with iota-carrageenan “
„ Marinomed - Ongoing SARS-CoV-2 clinical trials with iota-carrageenan “
„ Marinomed - SARS-CoV-2 and its variants will stay with us “
„ Marinomed - Carragelose® – Clinically validated for the prevention of COVID-19 “
„ Marinomed - Carragelose® Products “
„ Marinomed - Marinomed Pipeline “
„ Marinomed - Marinosolv® development status “
„ Marinomed - Budesolv and Flutisolv target the dynamic Allergic Rhinitis (AR) market “
„ Marinomed - Phase II clinical trial for Tacrosolv in allergic conjunctivitis “
„ Marinomed - Tacrosolv – potential game changer in the treatment of inflammatory eye diseases “
„ Marinomed - Financials “
„ Marinomed - Significant year-over-year growth also for Q1 “
„ Marinomed - Statement of profit or loss “
„ Marinomed - Statement of financial position (IFRS) “
„ Marinomed - Statement of financial position (IFRS) “
„ Marinomed - Outlook “
„ Marinomed - Strong development, however, with uncertainty in timing “
„ Marinomed - Stay Healthy! “
„ Marinomed - www.marinomed.com “
„ Marinomed - Investor Relations Contact “
